Helsinn Healthcare S.A. v. Sagent Pharmaceuticals

I'll research this case systematically, starting with the docket and patent background.

Good foundation. Now let me verify the docket history, the settlement-enforcement ruling, and IPR linkage.

Case Overview & Background

The parties. Plaintiff Helsinn Healthcare S.A. is not a patent troll or a university — it is a Swiss, family-controlled specialty pharmaceutical group headquartered in Lugano (founded by the Braglia family; group GM Giorgio Calderari is a named inventor on the patents). Helsinn's US business is run through Helsinn Therapeutics (U.S.), Inc. in Iselin, New Jersey. Helsinn in-licensed palonosetron from Roche Palo Alto LLC in 1998 (Roche's Syntex unit had run the Phase I/II work), finished development, and commercialized ALOXI® (palonosetron hydrochloride injection) under NDA No. 021372, with the formulation patents co-assigned to Helsinn and Roche Palo Alto. Defendant Sagent Pharmaceuticals, Inc. (Schaumburg, Illinois) is a generic injectables manufacturer — a classic Hatch-Waxman ANDA defendant, not a non-practicing entity (it was later absorbed into Japan's Nichi-Iko group). The docket-style caption lists Helsinn alone, though some records show "Helsinn Healthcare S.A., et al." because Roche was a co-assignee of the '725 patent. (Sagent br., D.I. 53; Bullock Decl., D.I. 48-1; D. Del. C.A. No. 13-688-GMS claim construction order)

The accused product. Sagent filed two ANDAs — No. 205870 and No. 204289 — seeking approval for generic palonosetron hydrochloride injection, 0.25 mg (base)/5 mL (i.e., 0.05 mg/mL), single-use vials, bioequivalent to ALOXI and carrying Paragraph IV certifications against Helsinn's Orange Book patents. Helsinn filed this suit on January 11, 2016, within the 45-day window after Sagent's Paragraph IV notice for the first ANDA, and filed a companion suit on February 8, 2016 (Civ. A. No. 16-681) on the second ANDA. Both Sagent ANDAs had tentative approval from FDA — fully approvable but for the first-filers' 180-day exclusivity — which is what makes this case a launch-timing dispute rather than a pure merits case. (Sagent br., D.I. 53; Sagent supp. br., D.I. 71)

The patents. The case metadata centers on U.S. Patent No. 7,947,725 ("Liquid pharmaceutical formulations of palonosetron"; App. No. 11/388,268, filed Mar. 24, 2006; priority to a Jan. 30, 2003 provisional; Orange Book expiry July 30, 2024). In one line: the '725 claims a shelf-stable injectable solution of palonosetron HCl at 0.03–0.2 mg/mL in an aqueous carrier at pH 4–6 with mannitol as tonicifier and 0.005–1.0 mg/mL EDTA — i.e., the 0.05 mg/mL formulation that delivers the 0.25 mg/5 mL dose. Note a documentation wrinkle: Sagent's own briefs describe five "Asserted Patents" listed in the complaints — the '725 plus '724, '424, '219 and '094 — so the '725 is the patent this case is indexed on, while the pleadings swept in Helsinn's full palonosetron Orange Book family. (DrugPatentWatch '725 record; Sagent br., D.I. 53; [FDA approval letter, ANDA 090713](https://www.accessdata.fda.gov/drugsat

I'll research this case across PACER-related sources, court opinions, PTAB records, and legal press.

Let me pull the full docket and the key orders.

Now let me find the July 2018 ruling on Sagent's motion to enforce, and check PTAB proceedings on the '725 patent.

Helsinn Healthcare S.A. v. Sagent Pharmaceuticals, Inc., No. 2:16-cv-00173 (SRC)(CLW) (D.N.J.)

A note on scope before the chronology. The case metadata lists only the '725 patent, but the complaint in fact asserted five Orange Book patents — U.S. Patent Nos. 7,947,724, 7,947,725, 7,960,424, 8,598,219, and 8,729,094 — against Sagent's palonosetron HCl ANDAs. Helsinn's counsel described the '725 as one of "the Asserted Patents." (D.I. 71 at 6; D.I. 53 at 3–4.) Also note that this docket is short and unusual: the merits case was settled and dismissed within seven months of filing, and the only substantive litigation in the docket occurred in 2018, when Sagent moved to reopen and enforce the settlement.

---

1. Filing and initial pleadings (2016)

2016-01-11 — Complaint filed. Helsinn Healthcare S.A. and Roche Palo Alto LLC sued Sagent in D.N.J. (originally before Judge Mary L. Cooper / Mag. J. Douglas E. Arpert), Civil Action No. 16-173, over Sagent's ANDA No. 205870 (palonosetron HCl injection, eq. 0

I'll research the docket and counsel appearances for this case.

Good leads. Let me verify the actual appearances on this docket (as opposed to the companion 16-681 case).

Let me pull the docket sheet itself to confirm which attorneys actually entered appearances in this case.

Bottom line

Helsinn was represented by a two-firm team: Paul Hastings LLP (New York) as national/merits counsel and Saul Ewing LLP (Newark, N.J.) as New Jersey local counsel of record. The attorneys whose appearances I can actually confirm on the 2:16-cv-00173 docket are Charles M. Lizza, Eric W. Dittmann, Isaac S. Ashkenazi, and Angela C. Ni (with William C. Baton and Sarah Ann Sullivan appearing on the parallel Sagent case, 16-681). Anything beyond that roster is inference, and I flag it as such below.

---

Counsel of record — confirmed on the docket

Firm allocation corroboration: Helsinn's June 5, 2018 letter to Judge Chesler in the settlement‑enforcement phase (D.I. 58) states: "This firm, together with Paul Hastings LLP, represents plaintiff Helsinn Healthcare S.A." — and it went out on Saul Ewing letterhead over Charles M. Lizza's signature. (D.I. 58 PDF)

---

Attorneys on the Helsinn team whose appearance in this case I could not confirm

These names appear on Helsinn's pleadings or PTAB papers in the related ALOXI matters, but I did not find a Notice of Appearance for them on the 16‑173 docket. Treat them as "team members in related Helsinn matters," not necessarily counsel of record here.

• Joseph M. O'Malley, Jr. — Paul Hastings, New York (200 Park Ave.). Helsinn's long-time lead appellate/merits counsel (argued the Helsinn v. Teva appeal that produced the Supreme Court's Helsinn v. Teva, 586 U.S. 731 (2019) on-sale bar decision). He is styled "Of Counsel" on Helsinn filings in D.N.J. 11‑3962, and is on the complaint caption in the companion case 16‑681, which lists him alongside Dittmann, Young J. Park, Ashkenazi, Ni, Gary Ji, and Dana Weir.
• William C. Baton and Sarah Ann Sullivan — Saul Ewing LLP, Newark. Both filed Notices of Appearance for Helsinn/Roche Palo Alto in the parallel 2:16-cv-00681 action (Plainsite docket); their 16‑173 appearances are likely but not verified.
• Young J. Park, Gary Ji, Dana Weir — Paul Hastings, New York. Park examined trial witnesses in the Helsinn ALOXI bench trial and handled the ALOXI PGRs; all appear on related Helsinn filings.
• Naveen Modi and Michael A. Stramiello, Ph.D. — Paul Hastings, Washington, D.C. PTAB-side counsel for Helsinn (identified as lead/back-up counsel in Helsinn's patent owner submissions); not D.N.J. litigation counsel here.

---

Sourcing notes and caveats

1. Docket jurisdiction history. The case was filed January 11, 2016 in the Camden vicinage as 3:16-cv-00173-MLC-DEA (Cooper/Arpert), then reassigned and renumbered as 2:16-cv-00173-SRC-CLW (Chesler/Waldor). Both numbers appear in the record — e.g., the April 5, 2016 order granting withdrawal of pro hac vice motions references "23 in 3:16-cv-00173-MLC-DEA." Any PACER pull should search both.
2. Docket overlap confusion. CourtListener's docket 6127735 for 2:16-cv-00173 includes filings by Akorn and Ingenus (answers/counterclaims, Feb. 2016) alongside Sagent's — Helsinn filed coordinated ALOXI actions against multiple ANDA sponsors in early 2016, and the aggregated docket reflects that. This is why the caption metadata here names only Sagent.
3. No in-house counsel appears. Helsinn Healthcare S.A. is a Swiss company (Lugano‑Pazzallo); no Helsinn legal‑department attorney entered an appearance. The docket shows no Rule 26.1/FRCP 7.1 in-house disclosure identifying legal staff.
4. Not sealed. Appearances here are public; nothing about the counsel roster is under seal. Certain settlement agreement filings were filed under seal/redacted (D.I. 51, 53, 71, 77–78), but those concern the Dr. Reddy's and Sandoz settlements, not counsel.
5. Who opposed whom in the 2018 enforcement fight (useful color, and confirms the alignments): Helsinn — Saul Ewing (Lizza) + Paul Hastings; Sagent — Carella, Byrne, Cecchi, Olstein, Brody & Agnello, P.C. (Melissa E. Flax, Michael Cross; Roseland, N.J.) + Taft Stettinius & Hollister LLP (Stephen R. Auten, Brian P. Murray; Chicago).
6. What I could not verify: I did not obtain a PACER‑authenticated docket sheet for 16‑173 (CourtListener's RECAP page was the best available proxy), so I have not confirmed whether O'Malley or Baton formally entered in this case, whether any § 42.8‑style pro hac vice orders issued for the Paul Hastings lawyers, or whether any appearances were later withdrawn. If precise entry‑by‑entry confirmation matters (e.g., for a fee/disqualification issue), pull the PACER docket for 2:16-cv-00173 and check the Notice of Appearance entries at Dkt. 9–12 (late January 2016) and the March 2016 answer‑to‑counterclaim signature block.

I'll research the docket and counsel of record for Sagent Pharmaceuticals in this D.N.J. case.

I have solid preliminary hits. Let me pull the full docket and confirm early appearances (2016) versus settlement-phase counsel.

Now let me check the 2016 pre-settlement phase counsel (the answer/warnings) and Melissa Flax's background.

Counsel of Record — Defendant Sagent Pharmaceuticals, Inc.

Bottom line: Sagent was represented by a two-firm team throughout: Carella Byrne Cecchi Olstein Brody & Agnell, P.C. (Roseland, N.J.) as New Jersey/local counsel, and Taft Stettinius & Hollister LLP (Chicago, Ill.) as lead Hatch-Waxman counsel. The same team appeared in the January 2016 case and later reappeared in 2018 to prosecute Sagent's motion to enforce the settlement agreement.

Docket basis

• D.I. 18 (Apr. 19, 2016) — Consent order granting admission pro hac vice of Stephen R. Auten and Brian P. Murray.
• D.I. 20–21 (May 4, 2016) — Notices of request for NEF by Auten and Murray (filed by Melissa E. Flax); both added to the electronic service list.
• D.I. 28 — Letter from Melissa E. Flax to Magistrate Judge Waldor.
• D.I. 46-1, 51-1, 53, 70, 71 (2018) — Sagent's motion to enforce the Settlement and License Agreement and supporting declarations/briefs, all captioned for Carella Byrne + Taft, with Auten, Murray, Flax and Cross named.

Source mirrors used: CourtListener/RECAP docket no. 6127735 (https://www.courtlistener.com/docket/6127735/helsinn-healthcare-sa-v-sagent-pharmaceuticals-inc/) and the PlainSite docket reproduction (https://www.plainsite.law/courts/new-jersey-district-court/helsinn-healthcare-sa-et-al-v-sagent-pharmaceuticals-inc/3aj3ygoi1/). I did not have direct PACER access, so entry-level detail comes from these RECAP-derived mirrors.

Caveats and things not to overstate

• No appearance was ever made by a Sagent in-house lawyer in this docket, and no Answer was filed — the case was dismissed by consent judgment on Aug. 2, 2016 (D.I. 27) while Sagent's response deadline was still being extended by consent orders (D.I. 19, 23). Counsel's appearances therefore date to the pro hac vice admissions in April–May 2016, not to a litigated answer.
• The 2018 enforcement phase is the same case number but a reopened/reinstated proceeding (FJC IDB lists a May 16, 2018 reopening; case reassigned from Judge Mary L. Cooper/Magistrate Judge Arpert to Judge Stanley R. Chesler/Magistrate Judge Cathy L. Waldor on May 14, 2018). The parallel Sagent action, No. 3:16-cv-00681, used the identical defense team.
• Brian P. Murray's and Michael Cross's individual patent-litigation track records are not independently verified here; I found no standalone firm bio or notable-case record for either. I have not attributed any specific past case to them. Auten's background is well documented on Taft's site (https://www.taftlaw.com/people/stephen-r-auten/).
• Several Sagent filings (D.I. 53, 57, 71, 77) were filed under seal or in redacted form; the caption blocks identifying counsel were visible, but sealed exhibits — including the July 25, 2016 Settlement and License Agreement — are not public.
• Correction to a common search artifact: the Frank R. Lautenberg letter at D.I. 58 naming Charles M. Lizza is plaintiff's counsel (Saul Ewing, with Paul Hastings as of counsel), not Sagent's.